Resistance of urinary tract pathogens and the choice of antimicrobial therapy: deceptive simplicity


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Urinary tract infection (UTI) is one of the most common reasons for prescribing antibiotics in outpatient and inpatient settings. One of the main criteria for selecting antimicrobial drugs for treating UTI is data on the antibiotic resistance of uropathogens. The article discusses the difficulties in interpreting the results of antimicrobial sensitivity testing of uropathogens and the impact of antibiotic resistance of uropathogens on the clinical effectiveness of managing UTI.

Full Text

Restricted Access

About the authors

V. V Rafalskiy

Smolensk State Medical University of Minzdrav of Russia

Email: v.rafalskiy@mail.ru
Dr.Med.Sci., Prof. at the DepartmentofPharmaceutical Management and Economics

E. V Dovgan’

Smolensk Regional Clinical Hospital

Email: dovganrus@mail.ru
Ph.D., Head of the Department of Clinical Pharmacokinetics

References

  1. Foxman B., Brown P. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am 2003;17:227-241.
  2. Segagni Lusignani L., Blacky A., Starzengruber P., Diab-Elschahawi M., Wrba T., Presterl E. A national point prevalence study on healthcare-associated infections and antimicrobial use in Austria. Wien Klin Wochenschr 2016.
  3. Guay D.R. Contemporary management of uncomplicated urinary tract infections. Drugs. 2008;68:1169-1205.
  4. Mulvey M.A., Klumpp D.J., Stapleton A.E. Urinary Tract Infections. Second ed. 2017. Washington, DC: ASM Press. 675.
  5. Grabe M., Bartoletti R., Bjerklund Johansen T.E., Cai T., ÇekM., Köves B. et al. Guidelines on Urological Infections. In: European Association of Urology; 2015. Р. 86.
  6. Gupta K., Hooton T.M., Naber K.G., Wullt B., Colgan R., Miller L.G. et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103-120.
  7. Tandogdu Z., Wagenlehner F.M. Global epidemiology of urinary tract infections. Curr Opin Infect Dis. 2016;29:73-79.
  8. Rafalskiy V., Khodnevich L. Prevalence and risk factors ofuncomplicated uTi: multicentre study SONAR. Eur. Urol. 2008;3(Suppl.):267.
  9. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7:653-660.
  10. Tambyah P.A., Maki D.G. Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. Arch Intern Med. 2000;160:678-682.
  11. Kamat U.S., Fereirra A., Amonkar D., Motghare D.D., Kulkarni M.S. Epidemiology of hospital acquired urinary tract infections in a medical college hospital in Goa. Indian J. Urol. 2009;25:76-80.
  12. Bjerklund Johansen T.E., Cek M., Naber K., Stratchounski L.,Svendsen M.V., Tenke P. et al. Prevalence of hospital-acquired urinary tract infections in urology departments. Eur Urol. 2007;51:1100-1111.
  13. Лопаткин Н.А., Аполихин О.И., Пушкарь Д.Ю. и др. Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов. Российские национальные рекомендации. 2014
  14. Яковлев С.В., Сидоренко С.В., Рафальский В.В., Спичак Т.В. Стратегия и тактика рационального применения антимикробных средств в амбулаторной практике: Евразийские клинические рекомендации: Пре100 Принт; 2016
  15. Jorgensen J.H., Ferraro M.J. Antimicrobial susceptibility testing: a review of general principles and contemporary practices. Clin Infect Dis. 2009;49:1749-1755.
  16. Silley P. Susceptibility testing methods, resistance and breakpoints: what do these terms really mean? Rev Sci Tech. 2012;31:33-41.
  17. Institute CaLS. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement (M100-S24). In; 2014. Р. 230.
  18. Testing ECoAS. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, 2016. In; 2016.
  19. Tamma P.D., Sklansky D.J., Palazzi D.L., Swami S.K., Milstone A.M. Antibiotic susceptibility of common pediatric uropathogens in the United States. Clin Infect Dis. 2014;59:750-752.
  20. French G.L. Clinical impact and relevance of antibiotic resistance. Adv Drug Deliv Rev. 2005;57:1514-1527.
  21. MacGowan A.P., on behalf of the BSAC Working Parties on Resistance Surveillance. Clinical implications of antimicrobial resistance for therapy. J. Antimicrob. Chemother. 2008;62:ii105-114.
  22. Kuper K.M., Boles D.M., Mohr J.F., Wanger A. Antimicrobial susceptibility testing: a primer for clinicians. Pharmacotherapy. 2009;29:1326-1343.
  23. EUCAST. Clinical breakpoints. In; 2016.
  24. Miller L.G., Mehrotra R., Tang A.W. Does in vitro fluoroquinolone resistance predict clinical failure in urinary tract infections? Int J. Antimicrob Agents. 2007;29:605-607.
  25. Frimodt-Moller N. Correlation between pharmacokinetic/ pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J. Antimicrob Agents. 2002;19:546-553.
  26. EUCAST. Proposed modifications to EUCAST clinical breakpoints. In; 2013.
  27. Martinelli R., Lopes A.A., de Oliveira M.M., Rocha H. Amoxicillinclavulanic acid in treatment of urinary tract infection due to gramnegative bacteria resistant to penicillin. Antimicrob Agents Chemother. 1981;20:800-802.
  28. Stamey T.A., Fair W.R., Timothy M.M., Millar M.A., Mihara G., Lowery Y.C. Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N. Engl J. Med. 1974;291:1159-1163.
  29. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 24th informational supplement. CLSI document M100-S24. Wayne, PA: CLSI, 2014.
  30. Macgowan A. P., Surveillance BWPoR. Clinical implications of antimicrobial resistance for therapy. J. Antimicrob Chemother. 2008;62(Suppl. 2):ii105-114.
  31. Rex J.H., Pfaller M.A. Has antifungal susceptibility testing come of age? Clin Infect Dis. 2002;35:982-989.
  32. Talan D.A., Krishnadasan A., Abrahamian F.M., Stamm W.E., Moran G.J., Group EMINS. Prevalence and risk factor analysis of trimethoprimsulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis. 2008;47:1150-1158.
  33. Рафальский В.В., Ходневич Л.В. Влияние резистентности возбудителей инфекций мочевыводящих путей на исходы антибактериальной терапии. Урология. 2008;4:3-9
  34. Yamamoto S., Akiyama K., Yoshimoto T., Kanokogi M., Yabumoto H., Ihara H., et al. Clinical efficacy of oral administration of 200 mg gatifloxacin once daily for 3 days for the treatment of patients with uncomplicated cystitis. J. Infect Chemother. 2009;15:104-107.
  35. Grimm H. In vitro investigations with fosfomycin on Mueller-Hinton agar with and without glucose-6-phosphate. Infection. 1979;7:256-259.
  36. Crespo E., Roca de Vinals J.A. Evolution of bacterial sensitivity to fosfomycin in the Cindad Sanitaria ‘Francisco Franco’ in Barcelona. Chemotherapy. 1977;23(Suppl. 1):112-116.
  37. Dette G.A., Knothe H., Schonenbach B., Plage G. Comparative study of fosfomycin activity in Mueller-Hinton media and in tissues. J. Antimicrob Chemother. 1983;11:517-524.
  38. Andrews J.M., Baquero F., Beltran J.M., Canton E., Crokaert F., Gobernado M., et al. International collaborative study on standardization of bacterial sensitivity to fosfomycin. J. Antimicrob Chemother. 1983;12:357-361.
  39. Devlin T.M. Textbook of biochemistry : with clinical correlations. 7th ed. Hoboken, NJ: John Wiley & Sons; 2011.
  40. Murakawa T., Sakamoto H., Fukada S., Konishi T., Nishida M. Pharmacokinetics of fosmidomycin, a new phosphonic acid antibiotic. Antimicrob Agents Chemother. 1982;21:224-230.
  41. Kihlstrom E., Andaker L. Inability of gentamicin and fosfomycin to eliminate intracellular Enterobacteriaceae. J. Antimicrob Chemother. 1985;15:723-728.
  42. Sauermann R., Schwameis R., Fille M., Ligios M.L., Zeitlinger M. Cerebrospinal fluid impairs antimicrobial activity of fosfomycin in vitro. J. Antimicrob Chemother. 2009;64:821-823.
  43. Gobernado M., Santos M., Diosdado N., Perez F. The evolution of the sensitivity to fosfomycin over the past two years. Chemotherapy. 1977;23(Suppl. 1):99-103.
  44. Cagnacci S., Gualco L., Debbia E., Schito G.C., Marchese A. European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25:H4-ST 131 and O15:K52:H1 causing community-acquired uncomplicated cystitis. J. Clin Microbiol. 2008;46:2605-2612.
  45. FDA. Joint Meeting of the Antimicrobial Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee: Industry Perspective. In: FDA; 2015.
  46. Stein G.E. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther. 1999;21:1864-1872.
  47. Minassian M.A., Lewis D.A., Chattopadhyay D., Bovill B., Duckworth G.J., Williams J.D. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J. Antimicrob Agents. 1998;10:39-47.
  48. Warren J.W., Abrutyn E., Hebel J.R., Johnson J.R., Schaeffer A.J., Stamm W.E. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society ofAmerica (IDSA). Clin Infect Dis. 1999;29:745-758.
  49. Raum E., Lietzau S., von Baum H., Marre R., Brenner H. Changes in Escherichia coli resistance patterns during and after antibiotic therapy: a longitudinal study among outpatients in Germany. Clin Microbiol Infect. 2008;14:41-48.
  50. Рафальский В.В., Страчунский Л.С., Бабкин П.А., Валенская В.С. и соавт. Резистентность возбудителей неосложненных инфекций мочевых путей в России. Урология. 2006;5:34-37
  51. Палагин И.С., Сухорукова М.В., Дехнич А.В., Эйдельштейн М.В., Шевелев А.Н., Гринев А.В. и соавт. Современное состояние антибиотикорезистентности возбудителей внебольничных инфекций мочевых путей в России: результаты исследования «ДАРМИС» (2010-2011). Клиническая микробиология и антимикробная химиотерапия. 2012; 14:280-302
  52. Рафальский В.В., Страчунский Л.С., Кречикова О.И., Эйдельштейн И.А. и соавт. Резистентность возбудителей амбулаторных инфекций мочевыводящих путей по данным многоцентровых микробиологических исследований UTIAP-I и UTIAP-II. Урология. 2004;2:13-17
  53. Filimonova O.Y., Stolyarova L.G., Sidorenko S.V., Rott I.M., Lysenko T.I., Narkhova T.V. et al. The Species Composition ofAgents of Community-Acquired Infections of Urinary Tracts and Sensitivity of Main Uropathogens to Antibacterial Preparations in Moscow in 2013. Klin Lab Diagn. 2015;60:58-61.
  54. Shigemura K., Arakawa S., Miura T., Nakano Y., Tanaka K., Fujisawa M. Significance of fluoroquinolone-resistant Escherichia coli in urinary tract infections. Jpn J. Infect Dis. 2008,61:226-228.
  55. Sorlozano A., Jimenez-Pacheco A., de Dios Luna Del Castillo J., Sampedro A., Martinez-Brocal A., Miranda-Casas C. et al. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: a 7-year surveillance study. Am J. Infect Control. 2014;42: 1033-1038.
  56. Pobiega M., Wojkowska-Mach J., Chmielarczyk A., Romaniszyn D., Adamski P., Heczko P.B. et al. Molecular characterization and drug resistance of Escherichia coli strains isolated from urine from longterm care facility residents in Cracow, Poland. Med Sei Monit. 2013;19:317-326.
  57. Rattanaumpawan P., Nachamkin I., Bilker W.B., Roy J.A., Metlay J.P., Zaoutis T.E. et al. Risk factors for ambulatory urinary tract infections caused by high-MIC fluoroquinolone-susceptible Escherichia coli in women: results from a large case-control study. J. Antimicrob Chemother. 2015;70:1547-1551.
  58. Naber K.G., Llorens L., Kaniga K., Kotey P., Hedrich D., Redman R. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother. 2009;53:3782-3792.
  59. Suzuk S., Kaskatepe B., Avcikucuk H., Aksaray S., Basustaoglu A. The comparison of antibiotic susceptibilities of uropathogenic Escherichia coli isolates in transition from CLSI to EUCAST. Mikrobiyol Bui. 2015;49:494-501.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies